Nordson Corporation (NDSN) has recently been the subject of significant
institutional investment, which own 73% of the company. Despite a
10% drop in stock and a surprise in
cut in earnings and sales guidance, various firms including
Envestnet Asset Management and
Ossiam have boosted their stake in Nordson, while others, like
Royal London Asset Management, have reduced their holding. The company has reported
lower profit and flat sales for Q2, causing a downfall in the stock, however, many still consider Nordson as a
Dividend Aristocrat. Nordson's intention to acquire
Atrion aims to boost medical offerings. They posted Q2 results that boasted
strong EBITDA margins and have updated their annual guidance accordingly. Despite revenue disappointments which have caused concern among the investors. Nordson has made several strategic acquisitions, including a
$800 million purchase of
Atrion, a market leader in medical infusion. These acquisitions significantly strengthen their product offerings. The company's stock has had mixed recommendations from analysts, but still receives a 'Moderate Buy'. The appointment of new executives, including
Daniel Hopgood as Chief Financial Officer, intends to strengthen the corporation's leadership.
Nordson Corp NDSN News Analytics from Mon, 04 Aug 2014 07:00:00 GMT to Sun, 16 Jun 2024 22:42:48 GMT -
Rating 2
- Innovation 6
- Information -3
- Rumor 1
